Pulmonary Drug Delivery Devices Systems Market Scope And Analysis

Pulmonary Drug Delivery Systems Market Report Scope

Industry Developments and Future Opportunities:

The pulmonary drug delivery systems market report includes company positioning and concentration to evaluate the performance of competitors in the market. As per company press releases, below are a few initiatives taken by key players operating in the market:

• In March 2021, PARI Pharma GmbH received the authorization of LAMIRA Nebulizer System for delivery of Insmed’s drug product ARIKAYCE (amikacin liposome inhalation suspension) in Japan. Insmed received approval for ARIKAYCE by Japan’s Ministry of Health, Labour, and Welfare in March 2021. The approval of ARIKAYCE in the country follows earlier approvals in the US and Europe.
• In December 2020, the European Commission approved AstraZeneca’s Trixeo Aerosphere in the European Union for COPD. It is used in the treatment of adult patients suffering from moderate to severe COPD. Trixeo Aerosphere is a single-inhaler, fixed-dose triple-combination of formoterol fumarate, glycopyrronium bromide, with budesonide, and an inhaled corticosteroid, and delivered in a pressurized metered-dose inhaler.

Competitive Landscape and Key Companies:

The pulmonary drug delivery systems market forecast can help stakeholders plan their growth strategies. AstraZeneca, GlaxoSmithKline Plc, Novartis AG, Koninklijke Philips NV, Boehringer Ingelheim International GmbH, Cipla Inc., OMRON Corp., PARI GmbH, Glenmark Pharmaceuticals, and Gilbert Technologies are among the prominent players in the market. These companies focus on introducing new high-tech products, advancements in existing products, and geographic expansions to meet the growing consumer demand worldwide.